Adam Feuerstein

Adam Feuerstein, an insightful author at Stat News, joins the discussion to explore the intriguing world of 'zombie' biotech companies, assessing whether they can be revived or should return capital to investors. He delves into Stoke's collaboration with Biogen and highlights promising gene therapy data for Duchenne muscular dystrophy. The conversation also touches on ethical concerns in biotech fundraising, the challenges faced by Bluebird Bios, and potential mergers like SpringWorks with Merck KGaA, revealing shifting landscapes in the industry.

Special guest Adam Feuerstein joins hosts in discussing Q1 earning reports, ONO's acquisition of Deciphera, X4's FDA approval, COVID fatigue, Biden’s Cancer Moonshot, drugmaker lawsuits, FTC targeting 'junk' patents, and emerging safety concerns in MorphoSys' study. Other topics include BridgeBio spinning out an oncology company, US government reclassifying marijuana, and more industry insights.

Adam Feuerstein, a senior writer at Stat specializing in pharmaceuticals, delves into the FDA's controversial approval of Aduhelm, a $55,000 drug for Alzheimer's. He highlights the mixed responses from the scientific community regarding its effectiveness. The discussion also covers the ethical dilemmas tied to the drug's high cost and the implications for patients seeking hope in their treatment. Feuerstein raises critical questions about the relationship between the FDA and pharmaceutical companies, emphasizing the need for reform in drug approval processes.